Director/PDMR Share Dealings

Director/PDMR Share Dealings

May 1, 2015

Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that on April 30, 2015, Stock Appreciation Rights (“SARs”) and Restricted Stock Units (“RSUs”) were granted to Persons Discharging Managerial Responsibilities (“PDMRs”) under the Shire Long Term Incentive Plan 2015 (“LTIP”). SARs and RSUs will normally vest after three years, subject to any performance conditions being satisfied, with no consideration payable on these awards. The awards were granted over notional American Depositary Shares (“ADSs”) in the Company as follows:



Type of Award(1),(2)

Number of ADSs(3)

Exercise Price

Flemming OrnskovSAR26,398$245.48
Jeff PoultonSAR8,862$245.48
Mark EnyedySAR4,444$245.48
Ginger GregorySAR4,259$245.48
Phil VickersSAR4,259$245.48


(1)      SARs and RSUs granted under the LTIP correspond to SARs and Performance Share Awards (“PSAs”) granted under the legacy Shire Portfolio Share Plan, as referenced in the Directors’ Remuneration Report in the 2014 Annual Report and Accounts.
(2)      SARs and RSUs granted to Dr. Ornskov and Mr. Poulton and RSUs granted to the remainder of the PDMRs are subject to performance conditions. Upon normal vesting, any ADSs to be delivered to Dr. Ornskov and Mr. Poulton will be subject to a retention period of two years in accordance with the rules of the LTIP.
(3)      One ADS is equal to three Ordinary Shares of 5 pence each in the Company.

This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary 

For further information please contact:

Investor Relations

Sarah Elton-Farr
[email protected]
+44 1256 894157


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

Click here for the PDF version of this press release.